Discovery of spirocyclic-diamine inhibitors of mammalian acetyl CoA-carboxylase.
Kung, D.W., Griffith, D.A., Esler, W.P., Vajdos, F.F., Mathiowetz, A.M., Doran, S.D., Amor, P.A., Bagley, S.W., Banks, T., Cabral, S., Ford, K., Garcia-Irizarry, C.N., Landis, M.S., Loomis, K., McPherson, K., Niosi, M., Rockwell, K.L., Rose, C., Smith, A.C., Southers, J.A., Tapley, S., Tu, M., Valentine, J.J.(2015) Bioorg Med Chem Lett 25: 5352-5356
- PubMed: 26411795
- DOI: https://doi.org/10.1016/j.bmcl.2015.09.035
- Primary Citation of Related Structures:
5CTB, 5CTC, 5CTE - PubMed Abstract:
A novel series of spirocyclic-diamine based, isoform non-selective inhibitors of acetyl-CoA carboxylase (ACC) is described. These spirodiamine derivatives were discovered by design of a library to mimic the structural rigidity and hydrogen-bonding pattern observed in the co-crystal structure of spirochromanone inhibitor I. The lead compound 3.5.1 inhibited de novo lipogenesis in rat hepatocytes, with an IC50 of 0.30 μM.
Organizational Affiliation:
Worldwide Medicinal Chemistry, Groton, CT 06340, United States. Electronic address: daniel.w.kung@pfizer.com.